Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARG | Q86W56 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158266 | 0.79 | KDM4E (0.34) | — | |
| SCHEMBL14861553 | 0.75 | CA12 (0.35) | ALDH1A1MEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL23009276 | 0.74 | PIK3CD (0.33) | — | |
| SCHEMBL10252597 | 0.74 | PIK3CD (0.30) | — | |
| SCHEMBL4909752 | 0.74 | CA2 (0.46) | ALDH1A1SMN1; SMN2NAAA | |
| SCHEMBL19342028 | 0.73 | KDM4E (0.33) | — | |
| SCHEMBL22528995 | 0.73 | KDM4E (0.33) | NAAA | |
| SCHEMBL22290089 | 0.73 | NAAA (0.41) | ALDH1A1NAAA | |
| SCHEMBL13834914 | 0.72 | CA1 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL22339126 | 0.72 | PIK3CD (0.35) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | GBA1 871/4885DGAT1 4703/4885NPY5R 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.